A new study shows that withaferin A, a steroidal lactone isolated from Withania somnifera, can exert profound metabolic benefits in mice, including body-weight loss, reduced hepatic steatosis and improved glucose control.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tschöp, M.H. et al. Cell Metab. 24, 51–62 (2016).
Lee, J. et al. Nat. Med. 22, 1023–1032 (2016).
Liu, J., Lee, J., Salazar Hernandez, M.A., Mazitschek, R. & Ozcan, U. Cell 161, 999–1011 (2015).
Myers, M.G. Jr. et al. Cell Metab. 15, 150–156 (2012).
Kim, J.E. et al. PLoS One 8, e62068 (2013).
McKenna, M.K. et al. Cancer Biol. Ther. 16, 1088–1098 (2015).
Yang, H. & Dou, Q.P. Curr. Drug Targets 11, 733–744 (2010).
Kleinridders, A. et al. J. Clin. Invest. 123, 4667–4680 (2013).
Zhang, X. et al. Cell 135, 61–73 (2008).
Ma, X. et al. Cell Metab. 22, 695–708 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Matthias Tschöp is a scientific advisor to Novo Nordisk, ERX and Bionorica.
Rights and permissions
About this article
Cite this article
Pfluger, P., Tschöp, M. Obesity: will withaferin win the war?. Nat Med 22, 970–971 (2016). https://doi.org/10.1038/nm.4182
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4182